ClinicalTrials.Veeva

Menu

The Global PCHF-COVICAV Registry

University of Zurich (UZH) logo

University of Zurich (UZH)

Status

Unknown

Conditions

COVID-19
Cardiovascular Diseases
Heart Failure
Cardiovascular Risk Factor

Study type

Observational

Funder types

Other

Identifiers

NCT04390555
PCHF-COVICAV

Details and patient eligibility

About

Background: Coronavirus disease (COVID-19) is a tremendous challenge the modern world has never seen before and is overwhelming the capacities of healthcare systems worldwide. Patients with cardiovascular diseases, heart failure in particular, and cardiovascular risk factors seem to be at a very high risk if affected by COVID-19 - and vice versa there are more and more reports of cardiac manifestations with the viral disease.

Aim: The purpose of the study is to characterise the clinical course of adult inpatients with COVID-19 and concomitant cardiovascular affection in a worldwide, multicentre PCHF registry.

Methods: Retrospective and prospective data analysis. Data on demographic, clinical, selected laboratory, electrocardiography and echocardiography parameters, treatment and outcome will be collected. The principal investigator provides dedicated electronic case report form. The primary outcome is in-hospital mortality. The secondary endpoints will be ICU length of stay, hospital length of stay, the need and duration of invasive mechanical ventilation, cardiovascular hospitalisation after 3 and 6 months from index hospitalisation, all-cause and cardiovascular mortality after 3 and 6 months from index hospitalisation.

Enrollment

1,500 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult inpatients (≥18 years old) with laboratory-confirmed COVID-19.

Exclusion criteria

  • Age <18 years old.
  • Outpatients.

Trial design

1,500 participants in 2 patient groups

CV involvement
Description:
Patients with COVID-19 and preexisting cardiovascular diseases and/or cardiovascular risk factors (diabetes mellitus, arterial hypertension and/or dyslipidaemia).
Control
Description:
Patients with COVID-19 without preexisting cardiac involvement.

Trial contacts and locations

1

Loading...

Central trial contact

Sander Trenson, MD; Mateusz Sokolski, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems